Newsletter | June 1, 2021

06.01.21 -- Spray-Dried Dispersions Enable Local Delivery For Lung Cancer

Industry Insights
Are You Prepared To Move A Bioconjugate Candidate From Clinic To Market?

On June 10, 2021, experts at Lonza Pharma & Biotech will discuss how our expertise and integrated solutions can help overcome the challenges of bringing ADCs and other bioconjugates to market.

Converting From ELISA To Biacore SPR Assays

This article provides general guidance on how to convert an existing ELISA assay to a Biacore SPR-assay and, by doing so, shows how you can get results in less than half the time compared with ELISA.

Spray-Dried Dispersions Enable Local Delivery For Lung Cancer

Spray drying is a leading technology for particle engineering and particularly advantageous for manufacturing particles in the inhalable range of 1-5 microns. Learn more about spray drying through two case studies of inhaled dry powders.

Drug R&D Services Leader Implements A Collaborative Enterprise ELN To Advance Research

In a demanding and increasingly distributed research environment, drug discovery alliance companies can only attract and maintain collaborations by being responsive and providing high quality results as quickly as possible. What mattered to this BIOVIA customer in meeting collaboration demands, however, was being able to rapidly collect together project information to deliver reports and data, fulfill patent submissions, or leverage and build on past work.

A Q&A: Achieving Biologics License Application Success Using A Structured Approach

Drs. Jason Osman and John McGuire from Lonza Pharma & Biotech answer attendee questions from a recent webinar about Lonza’s structured approach to developing a CMC strategy.

Most Popular News
Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.